AV
AVBP.US ArriVent BioPharma, Inc. Common Stock
- Market cap
- USD 673M
- P/E
- -
- P/B
- 1.72x
- ROE
- -43.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Sep 2026.
Is AVBP.US undervalued?
Graham numberThe Graham number of ArriVent BioPharma, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ArriVent BioPharma, Inc. Common Stock fundamental analysis
No fundamental analysis for ArriVent BioPharma, Inc. Common Stock yet.
ArriVent BioPharma, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical …
Full company profileArriVent BioPharma, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ArriVent BioPharma, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 5.00M |
| Operating Income | -8.70M | -36.9M | -74.6M | -94.3M | -178M | -181M |
| EBITDA | -51.6M | -36.9M | -69.3M | -80.5M | -166M | -172M |
| Net Income | -51.6M | -36.9M | -69.3M | -80.5M | -166M | -169M |
| EPS | -40 | -1.10 | -2.17 | -2.56 | -4.32 | -3.41 |
| Balance Sheet | ||||||
| Total Assets | 43.0M | 183M | 163M | 275M | 333M | 417M |
| Total Liabilities | 1.82M | 8.37M | 11.8M | 17.3M | 25.9M | 23.6M |
| Shareholders' Equity | 41.2M | 174M | 151M | 258M | 307M | 393M |
| Cash & Short-term Investments | 37.3M | 163M | 150M | 219M | 313M | 393M |
| Total Debt | - | 139K | 317K | 176K | 14.0K | 256K |
| Cash Flow | ||||||
| Operating Cash Flow | -12.6M | -43.6M | -55.8M | -70.2M | -161M | -153M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -12.6M | -43.6M | -55.8M | -70.2M | -161M | -153M |
| Ratios | ||||||
| ROE | -125.2% | -21.2% | -45.8% | -31.2% | -54.1% | -43.0% |
| ROA | -119.9% | -20.2% | -42.5% | -29.3% | -49.9% | -40.5% |
| Net Profit Margin | - | - | - | - | - | -3,381.4% |
| Debt to Equity | - | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ArriVent BioPharma, Inc. Common Stock dividends
ArriVent BioPharma, Inc. Common Stock has not paid dividends in the last 5 fiscal years.
Who owns ArriVent BioPharma, Inc. Common Stock
- Insiders 1.47%
- Institutions 97.07%
- Public & others 1.46%
- Shares outstanding 51.7M
- Free float 32.0M
Top funds holding AVBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 2.46M | 4.98% | -3.63% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.49M | 3.02% | +11.15% | Sep 2026 |
| Fidelity Select Biotechnology | 1.32M | 2.68% | -2.34% | Aug 2026 |
| State Street® SPDR® S&P® Biotech ETF | 986K | 2.00% | +2.68% | Oct 2026 |
| iShares Russell 2000 ETF | 954K | 1.93% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 416K | 0.84% | +0.20% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 354K | 0.72% | -0.38% | Oct 2026 |
| Fidelity Growth Company Fund | 324K | 0.66% | 0.00% | Aug 2026 |
| Fidelity Small Cap Growth | 299K | 0.61% | 0.00% | Aug 2026 |
| Fidelity Enhanced Small Cap Core ETF | 290K | 0.59% | +0.27% | Oct 2026 |
| iShares Biotechnology ETF | 270K | 0.55% | -0.19% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 221K | 0.45% | +0.23% | Oct 2026 |
| Vanguard Russell 2000 ETF | 220K | 0.45% | +1.23% | Sep 2026 |
| Fidelity Extended Market Index | 191K | 0.39% | +11.83% | Sep 2026 |
| MEDICAL BioHealth EUR Acc | 189K | 0.38% | +98.79% | Aug 2026 |
| Fidelity Small Cap Growth K6 | 149K | 0.30% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 115K | 0.23% | 0.00% | Oct 2026 |
| E Fund Global Medi Inds Allc QDII CNY A | 106K | 0.21% | 0.00% | Jun 2026 |
| Schwab Small Cap Index | 92.0K | 0.19% | -0.11% | Sep 2026 |
| Fidelity Growth Company K6 | 90.7K | 0.18% | 0.00% | Aug 2026 |
Top institutions holding AVBP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 4.52M | 9.16% | +2.60% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 3.93M | 7.97% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.25M | 6.59% | +28.46% | Jun 2026 |
| Orbimed Advisors LLC | 3.03M | 6.14% | 0.00% | Jun 2026 |
| FMR Inc | 2.78M | 5.64% | -7.86% | Jun 2026 |
| Octagon Capital Advisors LP | 1.97M | 4.00% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.77M | 3.60% | +16.09% | Jun 2026 |
| Sofinnova Ventures | 1.70M | 3.44% | 0.00% | Jun 2026 |
| State Street Corp | 1.69M | 3.43% | +19.11% | Jun 2026 |
| Vivo Capital, LLC | 1.68M | 3.41% | +89.87% | Jun 2026 |
| Novo A/S | 1.50M | 3.04% | -22.77% | Jun 2026 |
| General Catalyst Group Management, LLC | 1.49M | 3.03% | 0.00% | Jun 2026 |
| Logos Global Management LP | 1.00M | 2.03% | +185.71% | Jun 2026 |
| Geode Capital Management, LLC | 973K | 1.97% | +21.03% | Jun 2026 |
| D. E. Shaw & Co LP | 872K | 1.77% | +136.45% | Jun 2026 |
| The Goldman Sachs Group Inc | 854K | 1.73% | +0.03% | Jun 2026 |
| HSG Holding Ltd | 663K | 1.35% | 0.00% | Jun 2026 |
| Point72 Asset Management, L.P. | 567K | 1.15% | -24.24% | Jun 2026 |
| Millennium Management LLC | 439K | 0.89% | +2.99% | Jun 2026 |
| UBS Group AG | 439K | 0.89% | -9.80% | Jun 2026 |
ArriVent BioPharma, Inc. Common Stock company profile
- Company name
- ArriVent BioPharma, Inc. Common Stock
- Ticker
- AVBP.US
- Exchange
- USA Stocks
- Listed since
- Jan 26, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 77
- Fiscal year end
- September
- Address
- 18 Campus Boulevard, Newtown Square, PA, United States, 19073
- Phone
- 628 277 4836
- Website
- arrivent.com
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
ArriVent BioPharma, Inc. Common Stock management
7- Dr. Zhengbin Yao Ph.D.Co-Founder, Chairman, President & CEO · born 1966
- Dr. Stuart Lutzker M.D., Ph.D.Co-Founder, President of Research & Development and Director · born 1961
- Mr. Winston Kung M.B.A.CFO & Treasurer · born 1976
- Ms. Robin LaChapelle M.A.Co-Founder & COO · born 1973
- Ms. Yang Wang Ph.D.Chief Technology Officer
- Dr. James Paul Kastenmayer J.D., Ph.D.General Counsel & Secretary · born 1972
- Mr. Brent S. RiceChief Commercial Officer · born 1966